Orca-Q produced to high engraftment rates and promising survival outcomes in high-risk hematologic malignancies with haploidentical donors.
Exploring Alternate Allogeneic Immunotherapy Strategies in Hematologic Oncology
Orca-T was associated with OS, RFS, and NRM improvements in patients with hematologic malignancies who also received myeloablative conditioning.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5